^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Excerpt:
...PD-L1 low or negative expression (tumor proportion score [TPS] < 50%) 3....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

Excerpt:
...tumor infiltrating lymphocytes in patients whose tumors have a low PD_L1 expression`Immune biomarkers`infiltrating T cells that upregulate PD-1`inhibitory receptors such as TIM-3, LAG-3 and TIGIT`type of cells being positive for PD-L1(neoplastic cells vs infiltrating immune cells)`presence and phenotype of tumor-infiltrating lymphocytes in the pre-therapy lesions of patients with low expression of PD-L1`levels of CD3+, CD4+, CD8+ lymphocytes`expression, in TIL, of markers of functional differentiation to cytolytic stage such as granzyme B and TIA-1, or maturation to memory stage (CD45RO)`expression of PD1+ by TIL`expression of PD-L1 on neoplastic cells vs immune cells`expression of inhibitory receptors as LAG-3, TIM-3 and TIGIT`frequency of FOXP3+ lymphocytes, as well as of CD11b+ CD33+ MDSCs, in pre-therapy lesions...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%

Published date:
08/08/2023
Excerpt:
After 5 years of follow-up, pembrolizumab plus chemotherapy provided clinically meaningful improvements in survival outcomes and durable long-term clinical benefit versus chemotherapy alone with manageable safety in metastatic NSCLC with PD-L1 TPS <1%. These results continue to support the use of pembrolizumab plus chemotherapy as a standard of care first-line therapy for metastatic NSCLC, including in tumors with PD-L1 TPS <1%.
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-L1 Expression

Published date:
08/08/2023
Excerpt:
This study aims to retrospectively compare the treatment efficacy of first-line chemoimmunotherapy and chemotherapy alone in NSCLC patients with low PD-L1 expression....Patients who received chemoimmunotherapy demonstrated a significantly longer median PFS of 7.3 months (interquartile range [IQR] 5.1-13.3) compared to patients who received chemotherapy alone (4.9 months, IQR 2.5-7.9) (p = 0.015). The implementation of chemoimmunotherapy was also confirmed as independent good prognostic factor for both PFS and OS.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Immunotherapy Outcomes in Individuals with Non-Small Cell Lung Cancer and Poor Performance Status

Published date:
02/22/2022
Excerpt:
...For patients with tumor PD-(L)1 expression <50%, there was also a statistically significant rwOS benefit for those who received treatment, either with combination pembrolizumab plus chemotherapy (adjusted HR = 0.39, 95% CI = 0.32–0.46) or pembrolizumab monotherapy (adjusted HR = 0.55, 95% CI = 0.41–0.70),...
DOI:
https://doi.org/10.1093/jncics/pkac013
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Immunotherapy Outcomes in Individuals with Non-Small Cell Lung Cancer and Poor Performance Status

Published date:
02/22/2022
Excerpt:
...For patients with tumor PD-(L)1 expression <50%, there was also a statistically significant rwOS benefit for those who received treatment, either with combination pembrolizumab plus chemotherapy (adjusted HR = 0.39, 95% CI = 0.32–0.46) or pembrolizumab monotherapy (adjusted HR = 0.55, 95% CI = 0.41–0.70),...
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1093/jncics/pkac013
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

Excerpt:
An exploratory analysis revealed that for patients with low PD-L1 expression, the median PFS was 4.6 vs 20.8 months for pembrolizumab with and without RT, respectively (p=0.004).
DOI:
10.1136/jitc-2020-001001